Innovative Portfolio DevelopmentWhitehawk Therapeutics is taking a swift and strategic approach to developing an innovative portfolio of ADCs.
Operational RunwayWhitehawk ended 2Q25 with $177.2M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2028.
Pipeline DevelopmentUpcoming catalysts include Investigational New Drug submissions for HWK-007 and HWK-016 by the end of 2025, with Phase 1 trial initiation expected shortly after.